Andrew McNeill

Andrew McNeill has held a variety of roles in the field of medical technology since 2003. Andrew began their career as a Post Doctoral Researcher at the University of St Andrews, before becoming a Director and Principal Scientist at Ambicare Health in 2008. In 2013, they moved to Taragenyx as the Chief Scientific Officer, and in 2015 they were appointed Chief Executive Officer of Fixed Phage Limited. In 2017, they became Chairman of Chromacity Ltd, and in 2018 they were appointed New Investments Manager of Eos Tech Investors and Managing Partner of EOS Advisory. In 2019, they became an Investor Director at ClinSpec Diagnostics Limited, and in 2020 they were appointed Investor Director of Cumulus Oncology.

Andrew McNeill attended the University of Leeds from 1997 to 2003, where they completed a BSc and PhD in Molecular Physics.